Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07698210
PHASE1

A Study of LY4178256 in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate how well LY4178256 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to check how much LY4178256 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 7 months and will include either 7 or 12 visits depending on the assigned treatment.

Official title: A Phase 1, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4178256 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2026-07

Completion Date

2028-02

Last Updated

2026-07-13

Healthy Volunteers

Yes

Interventions

DRUG

LY4178256

Administered intravenously (IV)

DRUG

Placebo

Administered IV

Locations (2)

Collaborative Neuroscience Network - CNS

Los Alamitos, California, United States

ICON

Salt Lake City, Utah, United States